• Cornelia M. Weyand
  • Jörg J. Goronzy


Despite the spatial closeness of blood vessels and inflammatory cells, blood vessel walls are infrequently targeted by inflammation. Giant cell arteritis (GCA) and Takayasu’s arteritis (TA) are characterized by inflammation directed against the vessel wall. GCA and TA display stringent tissue tropism and affect defined vascular territories in a preferential manner. GCA predominantly affects the second- to fifth-order aortic branches, often in the extracranial arteries of the head. The aorta itself may also be affected in GCA, albeit less often than other regions. In contrast, in TA, the aorta and its major branches are the prime disease targets.


Giant Cell Arteritis Polymyalgia Rheumatica Small Vessel Vasculitis Large Vessel Vasculitis Temporal Artery Biopsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997;811:195–219.CrossRefGoogle Scholar
  2. 2.
    Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160–169.PubMedCrossRefGoogle Scholar
  3. 3.
    Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004;1992:173–183.CrossRefGoogle Scholar
  4. 4.
    Weyand CM, Wagner AD, Bjornsson J, et al. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;987:1642–1649.CrossRefGoogle Scholar
  5. 5.
    Rittner HL, Kaiser M, Brack A, et al. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999;849:1050–1058.Google Scholar
  6. 6.
    Weyand CM, Tetzlaff N, Bjornsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;401:19–26.CrossRefGoogle Scholar
  7. 7.
    Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999;425:844–853.CrossRefGoogle Scholar
  8. 8.
    Kaiser M, Weyand CM, Bjornsson J, et al. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998;414:623–633.CrossRefGoogle Scholar
  9. 9.
    Kaiser M, Younge B, Bjornsson J, et al. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999;1553:765–774.Google Scholar
  10. 10.
    Rittner HL, Hafner V, Klimiuk PA, et al. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999;1037:1007–1013.CrossRefGoogle Scholar
  11. 11.
    Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;1396:505–515.Google Scholar
  12. 12.
    Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999;422:311–317.CrossRefGoogle Scholar
  13. 13.
    Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;4812:3522–3531.CrossRefGoogle Scholar
  14. 14.
    Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;1227:502–507.Google Scholar
  15. 15.
    Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002;2871:92–101.CrossRefGoogle Scholar
  16. 16.
    Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;435:1041–1048.CrossRefGoogle Scholar
  17. 17.
    Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum 2004;511:128–139.CrossRefGoogle Scholar
  18. 18.
    Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002;1374:232–238.Google Scholar
  19. 19.
    Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002;804:355–367.CrossRefGoogle Scholar
  20. 20.
    Hoffman GS, Cinta-Cid M, Hellmann D, et al. A multicenter placebo-controlled study of methotrexate (MTX) in giant cell ateritis (GCA). Arthritis Rheum 2000;43:S115.CrossRefGoogle Scholar
  21. 21.
    Hoffman GS, Cinta-Cid M, Rendt KE, et al. Prednisone and infliximab for giant cell arteritis: a randomized, double-blind, placebo-controlled, multicenter study of efficacy and safety. Ann Int Med 2007;146:621–630.PubMedGoogle Scholar
  22. 22.
    Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis: induction therapy with high dose glucocorticoids. Arthritis Rheum 2006;54:3310–3318.PubMedCrossRefGoogle Scholar
  23. 23.
    Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332–1337.PubMedCrossRefGoogle Scholar
  24. 24.
    Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;3474:261–271.CrossRefGoogle Scholar
  25. 25.
    Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheuma-tica and giant cell arteritis. Ann Intern Med 1994;1217:484–491.Google Scholar
  26. 26.
    Weyand CM, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;1596:577–584.CrossRefGoogle Scholar
  27. 27.
    Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997;1271:27–31.Google Scholar
  28. 28.
    Kerr GS. Takayasu’s arteritis. Rheum Dis Clin North Am 1995;214:1041–1058.Google Scholar
  29. 29.
    Numano F. Differences in clinical presentation and outcome in different countries for Takayasu’s arteritis. Curr Opin Rheumatol 1997;91:12–15.CrossRefGoogle Scholar
  30. 30.
    Seko Y. Takayasu arteritis: insights into immunopathology. Jpn Heart J 2000;411:15–26.CrossRefGoogle Scholar
  31. 31.
    Kimura A, Kitamura H, Date Y, et al. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol 1996;54(Suppl):S61–S69.PubMedCrossRefGoogle Scholar
  32. 32.
    Kissin EY, Merkel PA. Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 2004;161:31–37.CrossRefGoogle Scholar
  33. 33.
    Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005;171:16–24.CrossRefGoogle Scholar
  34. 34.
    Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994;12011:919–929.Google Scholar
  35. 35.
    Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997;234:841–853.CrossRefGoogle Scholar
  36. 1.
    Kussmaul A, Maier R. Ueber eine bisher nicht beschriebene eigenthumliche arterienerkrankung (periar-teritis nodosa), die mit morbus brightii und rapid fortschreitender allgemeiner muskellahmung einhergeht. Dtsch Arch Klin Med 1866;1:484–518.Google Scholar
  37. 2.
    Matteson EL. Polyarteritis nodosa: commemorative translation of the 130-year anniversary of the original article by Adolf Kussmaul and Rudolf Maier. Rochester, MN: Mayo Foundation; 1996.Google Scholar
  38. 3.
    Jennette J, Falk R, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–192.PubMedCrossRefGoogle Scholar
  39. 4.
    Stone JH. Polyarteritis nodosa. JAMA 2002;288:1632–1639.PubMedCrossRefGoogle Scholar
  40. 5.
    Lightfoot RW, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088–1093.PubMedCrossRefGoogle Scholar
  41. 6.
    Levine SM, Hellman DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986–2000): presentation and outcomes in 24 patients. Am J Med 2002;112:386–391.PubMedCrossRefGoogle Scholar
  42. 7.
    Tervaert JWC, Kallenberg C. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 1993;19:913–940.PubMedGoogle Scholar
  43. 8.
    Gibson LE, Su WP. Cutaneous vasculitis. Rheum Dis Clin North Am 1995;21:1097–1113.PubMedGoogle Scholar
  44. 9.
    Conn DL. Polyarteritis. Rheum Dis Clin North Am 1990;16:341–362.PubMedGoogle Scholar
  45. 10.
    Hunder GH, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 1990;33:1065–1067.PubMedCrossRefGoogle Scholar
  46. 11.
    Gayraud M, Guillevin L, Le Toumelin P, et al. Long term follow up of polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666–675.PubMedCrossRefGoogle Scholar
  47. 12.
    Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17–28.CrossRefGoogle Scholar
  48. 13.
    De Groot K, Adu D, Savage COS. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018–2027.PubMedCrossRefGoogle Scholar
  49. 1.
    Godman G, Churg J. Wegener’s granulomatosis: pathology and review of the literature. Arch Pathol Lab Med 1954;58:533.Google Scholar
  50. 2.
    Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;1:425–429.PubMedGoogle Scholar
  51. 3.
    Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;318:1651–1657.PubMedCrossRefGoogle Scholar
  52. 4.
    Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101–1107.PubMedCrossRefGoogle Scholar
  53. 5.
    Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094–1100.PubMedCrossRefGoogle Scholar
  54. 6.
    Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–1128.PubMedCrossRefGoogle Scholar
  55. 7.
    Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–192.PubMedCrossRefGoogle Scholar
  56. 8.
    Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995;25:28–34.PubMedCrossRefGoogle Scholar
  57. 9.
    Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–498.PubMedGoogle Scholar
  58. 10.
    Stone JH for the WGET Research Group. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299–2309.Google Scholar
  59. 11.
    Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521–1537.PubMedGoogle Scholar
  60. 12.
    Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecu-tive patients with possible ANCA-associated conditions. Arthritis Care Res 2000;13:424–434.PubMedCrossRefGoogle Scholar
  61. 13.
    Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025–2033.PubMedCrossRefGoogle Scholar
  62. 14.
    Finkielman JD, Merkel PA, Schroeder D, et al. Antineutrophil cytoplasmic antibodies against proteinase 3 do not predict disease relapses in Wegener’s granulomatosis. Ann Intern Med 2007, (in press).Google Scholar
  63. 15.
    Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955–963.PubMedGoogle Scholar
  64. 16.
    Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloper-oxidase antibodies. Arthritis Rheum 2000;43:405–413.PubMedCrossRefGoogle Scholar
  65. 17.
    Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180–187.PubMedCrossRefGoogle Scholar
  66. 18.
    Wung PK, Stone JH. Therapeutics for Wegener’s granulomatosis. Nat Clin Pract Rheumatol 2006;2:192–200.PubMedCrossRefGoogle Scholar
  67. 19.
    WGET Research Group. Design of the Wegener’s Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002;23:450–468.CrossRefGoogle Scholar
  68. 20.
    Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.PubMedCrossRefGoogle Scholar
  69. 21.
    Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666–2673.PubMedCrossRefGoogle Scholar
  70. 22.
    The WGET Research Group. Etanercept in addition to standard therapy in patients with Wegener’s granulomatosis. N Engl J Med 2005;352:351–361.CrossRefGoogle Scholar
  71. 23.
    Stone JH, Holbrook JT, Tibbs A, et al. Solid malignancies in the Wegener’s granulomatosis Etanercept trial. Arthritis Rheum 2006;54:1608–1618.PubMedCrossRefGoogle Scholar
  72. 24.
    Hoffman GS, Thomas-Golbanov CK, et al. Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003;30:1017–1021.PubMedGoogle Scholar
  73. 25.
    Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776–784.PubMedCrossRefGoogle Scholar
  74. 26.
    Seo P, Min Y-I, Holbrook JT, et al. Damage from Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum 2005;52:2168–2178.PubMedCrossRefGoogle Scholar
  75. 1.
    Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005;9:183–191.PubMedCrossRefGoogle Scholar
  76. 2.
    Arthus M. Injections repetees de serum de cheval cuez le lapin. Seances et Memoire de la Societe de Biologie 1903;55:817–825.Google Scholar
  77. 3.
    Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990;33:1108–1113.PubMedCrossRefGoogle Scholar
  78. 4.
    Wintrobe MM, Buell MV. Hyperproteinemia associated with multiple myeloma: with report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud’s disease. Bulletin Johns Hopkins Hosp 1933;52:156.Google Scholar
  79. 5.
    Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006;18:54–63.PubMedGoogle Scholar
  80. 6.
    Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990;33:1114–1121.PubMedCrossRefGoogle Scholar
  81. 7.
    Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M, Gonzalez-Gay MA. Henoch-Schonlein purpura in adulthood and childhood: two different express-ions of the same syndrome. Arthritis Rheum 1997;40:859–864.PubMedCrossRefGoogle Scholar
  82. 8.
    Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schonlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001;21:128–133.PubMedCrossRefGoogle Scholar
  83. 9.
    Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am 2004;24:183–213.PubMedCrossRefGoogle Scholar
  84. 1.
    International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.Google Scholar
  85. 2.
    Kural-Seyahi E, Fresco I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore), 2003;82:60–76.CrossRefGoogle Scholar
  86. 3.
    Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet disease. Curr Opin Rheumatol 2005;17:1–8.PubMedCrossRefGoogle Scholar
  87. 4.
    Le Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behçet’s disease. A study in 25 patients. J Rheumatol 1995;22:2103–2113.PubMedGoogle Scholar
  88. 5.
    Hamuryudan V, Er T, Seyahi T, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004;117:867–870.PubMedCrossRefGoogle Scholar
  89. 6.
    Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behcet disease. A review. Neurologist 2005;11:80–89.PubMedCrossRefGoogle Scholar
  90. 7.
    Schirmer M, Calamia KT. Is there a place for large vessel disease in the diagnostic criteria for Behçet’s disease? J Rheumatol 1999;26:2511–2512.PubMedGoogle Scholar
  91. 8.
    Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s Disease. Semin Arthritis Rheum 1998;27:197–217.PubMedCrossRefGoogle Scholar
  92. 9.
    Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum 2001;44:2686–2692.PubMedCrossRefGoogle Scholar
  93. 10.
    Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet’s syndrome: Effects on long-term prognosis. Arthritis Rheum 1997;40:769–774.PubMedCrossRefGoogle Scholar
  94. 11.
    Kötter I, Zierhut M, Eckstein A, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423–431.PubMedCrossRefGoogle Scholar
  95. 12.
    Melikoglu M, Fresco I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98–105.PubMedGoogle Scholar
  96. 13.
    Takeno M, Kariyone A, Yamasita M, et al. Excessive function of peripheral blood neutrophils from patients with Behçet’s disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995;38:426–433.PubMedCrossRefGoogle Scholar
  97. 14.
    Hasan A, Fortune F, Wilson A, et al. Role of gamma delta T cells in pathogenesis and diagnosis of Behçet’s disease. Lancet 1996;347:789–794.PubMedCrossRefGoogle Scholar
  98. 15.
    Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet’s disease. Int Rev Immunol 1997;14:21–32.PubMedGoogle Scholar
  99. 16.
    Gul A. Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005;4:81–83.PubMedCrossRefGoogle Scholar
  100. 17.
    Lie, JT. Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 1992;23:164–171.PubMedCrossRefGoogle Scholar
  101. 18.
    Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 1988;67:20–39.Google Scholar
  102. 19.
    Calabrese LH, Gragg LA, Furlan AJ. Benign angiopathy: a distinct subset of angiographically defined primary angiitis of the central nervous system. J Rheumatol 1993;20:2046–2050.PubMedGoogle Scholar
  103. 20.
    Woolfenden AR, Tong DC, Marks MP, et al. Angiographically defined primary angiitis of the CNS: is it really benign? Neurology 1998;51:183–188.PubMedGoogle Scholar
  104. 21.
    Salvarani C, Hunder GG. Primary central nervous system vasculitis (PCNSV): Clinical features and outcome. Arthritis Rheum 2005(52 supplement):S650.Google Scholar
  105. 22.
    Gluth MB, Baratz KH, Matteson EL, et al. Cogan Syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 2006;81:483–488.PubMedCrossRefGoogle Scholar
  106. 23.
    McCallum RM, St. Clair EW, Haynes BF. Cogan’s Syndrome. In Hoffman GS, Weyand C, eds. Inflammatory Diseases of Blood Vessels. New York: Marcel Dekker, Inc.; 2002:491–509.Google Scholar
  107. 24.
    Wahl CE, Bouldin MB, Gibson LE. Erythema elevatum diutinum: clinical, histopathologic, and immunohistochemical characteristics of six patients. Am J Dermatopathol 2005;27:397–400.PubMedCrossRefGoogle Scholar
  108. 25.
    Gibson LE, el-Azhary RA. Erythema elevatum diutinum. Clin Dermatol 2000;18:295–299.PubMedCrossRefGoogle Scholar
  109. 1.
    Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967;16:178–222.PubMedGoogle Scholar
  110. 2.
    Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–276.PubMedGoogle Scholar
  111. 3.
    Takahashi M. Kawasaki syndrome (mucocutaneous lymph node syndrome). In: Emmanouilides GC, ed. Moss and Adams heart disease in infants, children, and adolescents: including the fetus and young adult. 5th ed. Baltimore: Williams & Wilkins, 1995:13909.Google Scholar
  112. 4.
    Spector S. Scarlett fever, periarteritis nodosa, aneurysm of the coronary artery with spontaneous rupture, hemopericardium. Arch Pediatr 1939;25:319.Google Scholar
  113. 5.
    Kato H, Ichinose E, Yoshioka F, et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982;49:1758–1766.PubMedCrossRefGoogle Scholar
  114. 6.
    Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986;108:923–927.PubMedCrossRefGoogle Scholar
  115. 7.
    Japan Kawasaki Disease Research Committee. Diagnostic guideline of Kawasaki disease. Tokyo: Japan Kawasaki Disease Research Committee; 1984.Google Scholar
  116. 8.
    American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. Diagnostic guidelines for Kawasaki disease. Am J Dis Child 1990;144:1218–1219.Google Scholar
  117. 9.
    Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776–1780.PubMedGoogle Scholar
  118. 10.
    Rowley AH, Gonzalez-Crussi F, Gidding SS, et al. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987;110:409–413.PubMedCrossRefGoogle Scholar
  119. 11.
    Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995;126:524–529.PubMedCrossRefGoogle Scholar
  120. 12.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in the young. American Heart Association. Circulation 2004;110:2747–2771.Google Scholar
  121. 13.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in the young. American Heart Association. Pediatrics 2004;114:1708–1733.Google Scholar
  122. 14.
    Taubert KA. Epidemiology of Kawasaki disease in the United States and worldwide. Prog Pediatr Cardiol 1997;6:181–185.CrossRefGoogle Scholar
  123. 15.
    Mason WH, Takahashi M, Schneider T. Recurrence of Kawasaki disease in a large urban cohort in the United States. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas: American Heart Association; 1993:21–26.Google Scholar
  124. 16.
    Taubert KA, Rowley AH, Shulman ST. A 10 year (1984–1993) United States hospital survey of Kawasaki disease. In: Kato H, ed. Kawasaki disease: proceedings of the 5th International Kawasaki Disease Symposium. New York: Elsevier; 1995:34–38.Google Scholar
  125. 17.
    Yanagawa H, Yashiro M, Nakamura Y, et al. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch Pediatr Adolesc Med 1995;149:779–783.PubMedGoogle Scholar
  126. 18.
    Barron KS, Shulman ST, Rowley A, et al. Report of the National Institutes of Health workshop on Kawasaki disease. J Rheumatol 1999;26:170–190.PubMedGoogle Scholar
  127. 19.
    Leung DY, Meissner HC, Shulman ST, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002;140:742–746.PubMedCrossRefGoogle Scholar
  128. 20.
    Leung DYM, Giorno RC, Kazemi LV, et al. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki disease. J Immunol 1995;155:5018–5021.PubMedGoogle Scholar
  129. 21.
    Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385–1388.PubMedCrossRefGoogle Scholar
  130. 22.
    Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992;89:4066–4070.PubMedCrossRefGoogle Scholar
  131. 23.
    Tomita S, Myones BL, Shulman ST. In vitro correlates of L. casei animal model of Kawasaki Disease. J Rheumatol 1993;20:362–367.PubMedGoogle Scholar
  132. 24.
    Duong TT, Silverman ED, Bissessar MV, et al. Superantigenic activity is responsible for induction of coronary arteritis in mice: and animal model for Kawasaki disease. Int Immunol 2003;15:79–89.PubMedCrossRefGoogle Scholar
  133. 25.
    Rowley AH, Eckerley CA, Jack HM, et al. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946–5955.PubMedGoogle Scholar
  134. 26.
    Rowley AH, Shulman ST, Spike BT, et al. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334–1343.PubMedGoogle Scholar
  135. 27.
    Laxer RM, Schaffer FM, Myones BL, et al. Lymphocyte abnormalities and complement activation in Kawasaki disease. Prog Clin Biol Res 1987;250:175–184.PubMedGoogle Scholar
  136. 28.
    Myones BL, Bathori JM, Tomita S, et al. Intravenous IgG infusions are associated with the in vitro inhibition of classical pathway-mediated lysis of sheep red blood cells and a decrease in C4d levels in Kawasaki disease. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Kawasaki Disease Symposium. Dallas: American Heart Association; 1993:412–418.Google Scholar
  137. 29.
    Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888–893.PubMedCrossRefGoogle Scholar
  138. 30.
    Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055–1058.PubMedCrossRefGoogle Scholar
  139. 31.
    Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341–347.PubMedCrossRefGoogle Scholar
  140. 32.
    Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633–1639.PubMedCrossRefGoogle Scholar
  141. 33.
    Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease. Circulation 1994;89:916–922.PubMedGoogle Scholar
  142. 34.
    Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175–179.PubMedGoogle Scholar
  143. 35.
    Wright DA, Newburger JW, Baker A, et al. Treat-ment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146–149.PubMedCrossRefGoogle Scholar
  144. 36.
    Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465–469.PubMedCrossRefGoogle Scholar
  145. 37.
    Hashino K, Ishii M, Iemura M, et al. Re-treatment of immunoglobulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211–217.PubMedCrossRefGoogle Scholar
  146. 38.
    Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611–616.PubMedCrossRefGoogle Scholar
  147. 39.
    Myones BL, Altman CA, Ayres N, et al. Imaging of coronary and peripheral arteries with magnetic resonance angiography (MRA) in infants with Kawasaki disease: a new utilization to guide therapy. Arthritis Rheum 2002;46:S309.CrossRefGoogle Scholar
  148. 40.
    Furukawa S, Matusubara T, Umezawa Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 1994;153:664–667.CrossRefGoogle Scholar
  149. 41.
    Best BM, Burns JC, DeVincenzo J, et al. Pharmacokinetics and tolerablility assessment of a pediatric oral formulation of pentoxifylline in Kawasaki disease. Curr Ther Res 2003;64:96–115.CrossRefGoogle Scholar
  150. 42.
    Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki Syndrome. J Pediatr 2005;146:662–667.PubMedCrossRefGoogle Scholar
  151. 43.
    Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808–810.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Cornelia M. Weyand
    • 1
  • Jörg J. Goronzy
    • 2
  1. 1.Kathleen B. and Mason I. Lowance Center for Human Immunology, Department of MedicineEmory University School of MedicineAtlantaUSA
  2. 2.Department of Medicine, Kathleen B. and Mason I. Lowance Center for Human ImmunologyEmory University School of MedicineAtlantaUSA

Personalised recommendations